Gainers

• CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 6.9% to $1.08 during Friday's after-market session. The market value of their outstanding shares is at $11.1 million.
• Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 6.26% to $0.25. The company's market cap stands at $8.5 million.
• Psyence Biomedical (NASDAQ:PBM) stock increased by 5.17% to $3.25. The market value of their outstanding shares is at $2.8 million.
• TScan Therapeutics (NASDAQ:TCRX) stock rose 5.13% to $0.98. The market value of their outstanding shares is at $53.0 million.
• Beyond Air (NASDAQ:XAIR) stock moved upwards by 4.76% to $1.1. The company's market cap stands at $8.7 million. As per the press release, Q3 earnings came out today.
• Polyrizon (NASDAQ:PLRZ) stock increased by 4.47% to $14.47. The market value of their outstanding shares is at $14.5 million.

Losers

• BioRestorative Therapies (NASDAQ:BRTX) shares declined by 8.8% to $0.26 during Friday's after-market session. The company's market cap stands at $2.1 million.
• AIM ImmunoTech (AMEX:AIM) stock decreased by 8.01% to $1.15. The company's market cap stands at $2.5 million.
• OKYO Pharma (NASDAQ:OKYO) shares declined by 8.0% to $1.61. The market value of their outstanding shares is at $88.0 million.
• Catheter Precision (AMEX:VTAK) shares decreased by 7.0% to $1.33. The company's market cap stands at $2.2 million.
• Quince Therapeutics (NASDAQ:QNCX) shares decreased by 3.91% to $0.19. The company's market cap stands at $12.5 million.
• SCWorx (NASDAQ:WORX) stock declined by 3.36% to $0.27. The company's market cap stands at $3.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.